



Biperiden

Catalog No: tcsc1797

Formula: $C_{21}H_{29}NO$

Pathway:

Neuronal Signaling; GPCR/G Protein

Target:

mAChR;mAChR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

KL 373

Observed Molecular Weight:

311.46

Product Description

Biperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker.





Target: M1 receptors

Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson\'s disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate. It also has a prominent central blocking effect on M1 receptors [2].

Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg), caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats\' innate preference for novelty, whereas biperiden and procyclidine did not [3].

Clinical indications: parkinsonism

FDA Approved Date:

Toxicity: Drowsiness; vertigo; headache; dizziness

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!